Floatz logo

Lecanemab

Familial Alzheimer Disease

Explore 5 assets in Familial Alzheimer Disease →
Floatz Rating
BB66/100
Confidence
Indicative
v0.2
Sponsor
Washington University School of Medicine
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05269394CT.gov
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
—Active Not Recruiting———
NCT01760005CT.gov
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Familial Alzheimer Disease

AssetSponsorPhaseRating
Lecanemab (this asset)Washington University School of MedicineP3BB · 66
Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, DimerWashington University School of MedicineP2/3B
RemternetugWashington University School of MedicineP2/3B
SolanezumabWashington University School of MedicineP2/3CCC
2-Bromo-?-ergocryptineKyoto UniversityP1/2CCC
Immunoglobulin G1, Anti-(Human 1-40-.Beta.-Amyloid/Human 1-42-.Beta.-Amyloid) (Human Monoclonal .Gamma.1-Chain), Disulfide With Human Monoclonal .Kappa.-Chain, DimerWashington University School of MedicineP2/3CC

Other indications for Lecanemab

IndicationSponsorPhaseRating
Alzheimer Disease—P4BB · 71
Dementia—P3B · 62
Alzheimer Disease Type 1—Early P1C · 39

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Lecanemab in Familial Alzheimer Disease. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/lecanemab-familial-alzheimer-disease

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →